Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

Olanzapine is widely used to treat schizophrenia and other disorders, but causes adverse obesity and other metabolic side-effects. Both animal and clinical studies have shown that co-treatment with betahistine (a histaminergic H1 receptor agonist and H3 receptor antagonist) is effective for ameliorating olanzapine-induced weight gain/obesity. To reveal the mechanisms underlying these effects, this study investigated the effects of co-treatment of olanzapine and betahistine (O+B) on expressions of histaminergic H1 receptor (H1R), AMP-activated protein kinase (AMPK), neuropeptide Y (NPY), and proopiomelanocortin (POMC) in the hypothalamus associated with reducing olanzapine-induced weight gain. Olanzapine significantly upregulated the mRNA and protein expressions of H1R, while O+B co-treatment significantly downregulated the H1R levels, compared to the olanzapine-only treatment group. The NPY mRNA expression was significantly enhanced by olanzapine, but it was significantly reversed by O+B co-treatment. The hypothalamic H1R expression was positively correlated with total food intake, and NPY expression. Olanzapine also increased AMPKα activation measured by the AMPKα phosphorylation (pAMPKα)/AMPKα ratio compared with controls, whereas O+B co-treatment decreased the pAMPKα/AMPKα ratio, compared with olanzapine only treatment. The pAMPKα/AMPKα ratio was positively correlated with total food intake and H1R expression. Although olanzapine administration decreased the POMC mRNA level, this level was not affected by O+B co-treatment. Therefore, these results suggested that co-treatment with betahistine may reverse olanzapine-induced body weight gain via the H1R-NPY and H1R-pAMPKα pathways.

Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis

Background

This systematic review aimed to compare body weight gain associated outcomes over time between dolutegravir (DTG)-based antiretroviral (ART) regimens to other ART regimens, to compare tenofovir alafenamide (TAF)-based regimens, and to evaluate the associated prognostic factors.

Methods

Systematic searches of MEDLINE, Embase, and CENTRAL for RCTs and observational studies comparing ART regimens were conducted on 13 September 2021. Outcomes of interest included: change in body weight, body mass index (BMI), waist circumference; and risk of hyperglycaemia and diabetes. Network meta-analyses were conducted at 12, 24, 48, 96 and 144 weeks using two networks differentiated by 3rd agents and backbone agents.

Findings

The review identified 113 publications reporting on 73 studies. DTG-based regimens led to statistically higher weight gains than efavirenz-based regimens at all time points (mean difference: 1·99 kg at 96 weeks; 95% credible interval: 0·85-3·09) and was higher over time than low-dose efavirenz-, elvitegravir-, and rilpivirine-based regimens. They were comparable to raltegravir-, bictegravir- and atazanavir-based regimens. For backbones, TAF led to higher weight gain relative to tenofovir disoproxil fumarate (TDF), abacavir, and zidovudine. Prognostic factor analysis showed both low CD4 cell count and high HIV RNA viral load at baseline were consistently associated with higher weight gain, while sex was an effect modifier to African origins.

Interpretation

DTG-based regimens lead to larger average weight gains than some other ART regimens and TAF leads to larger average weight gains than all other backbone antiretrovirals. Further research is needed to better understand long-term outcomes and their relationship to other metabolic outcomes.

Funding

The WHO Global HIV, Hepatitis and Sexually Transmitted Infections Programmes.

Body weight gain and risk of colorectal cancer: a systematic review and meta-analysis of observational studies

While the relationship between body mass index as an indicator of excess body weight and the risk of colorectal cancer (CRC) is well established, the association between body weight gain in adulthood and risk of CRC remains unresolved. We quantified this association in a meta-analysis of 12 observational studies published until November 2014 with a total of 16,151 incident CRC cases. Random effect models were used to obtain summary relative risks (RR) and 95% confidence intervals (95% CIs). Between-study heterogeneity was assessed using I(2) statistics. Overall, the summary RR (95% CI) was 1.22 (1.14-1.30) for high body weight gain (midpoint: 15.2 kg) compared with stable weight (P for heterogeneity = 0.182; I(2) = 21.2%). In a dose-response analysis, each 5 kg weight gain was associated with a 4% (95% CI: 2%-5%) higher risk of CRC. The association persisted after adjustment for body weight at younger age and was present for both men and women, as well as for colon and rectal cancer. Differences by sex were detected for colon cancer (P for interaction = 0.003, with higher risk for men than women), but not for rectal cancer (P for interaction = 0.613). In conclusion, these data underscore the importance of body weight management from early adulthood onwards for the prevention of CRC development.

Metabolic changes over the course of aging in a mouse model of tau deposition

Weight loss and food intake disturbances that often precede cognitive decline and diagnosis have been extensively reported in Alzheimer's disease patients. Previously, we observed that transgenic mice overexpressing tau seemed to eat more food yet weigh less than nontransgenic littermates. Thus, the present longitudinal study measured the time course of changes in metabolic state over the lifespan of the tau depositing Tg4510 mouse model of tau deposition. Although body weight was comparable to nontransgenic littermates at 2 months of age, Tg4510 mice weighed less at older ages. This was accompanied by the accumulation of tau pathology and by dramatically increased activity in all phases of the 24-hour cycle. Resting metabolic rate was also increased at 7 months of age. At 12 months near the end of the Tg4510 lifespan, there was a wasting phase, with a considerable decrease of resting metabolic rate, although hyperactivity was maintained. These diverse changes in metabolism in a mouse model of tau deposition are discussed in the context of known changes in energy metabolism in Alzheimer's disease.

The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood

AIM

Body weight gain adds risk for metabolic disorders and there are different metabolic changes in earlier and later adulthood. However, its impact on non-alcoholic fatty liver disease (NAFLD) was indeterminate. The aim of current study was to evaluate the impact of body weight gain on NAFLD and metabolic syndrome (MetS) during overall, earlier (25-40y) and later (over 40y) adulthood.

METHODS

1119 subjects were selected to calculate changes in body weight (ΔBW), body mass index (BMI) (ΔBMI) and bodyweight per year (ΔBW/y) to analysis their impact on NAFLD and MetS in multi-variable regression models, and explored the potential mediators that associated ΔBMI with NAFLD by mediation analysis.

RESULTS

ΔBMI, ΔBW and ΔBW/y in whole adulthood were all positively associated with NAFLD and MetS. Body weight gain during earlier adulthood was more strongly associated with NAFLD than those during later adulthood. In NAFLD, the ORs of ΔBMI (third trisection), ΔBW and ΔBW/y were 3.86 (2.25, 6.57), 1.05 (1.02, 1.09) and 2.05 (1.29, 3.24) during earlier adulthood, and 1.47 (1.09, 2.02), 1.02 (1.00, 1.06), and 1.04 (.99, 1.13) over 40y. Insulin and HOMA-IR were important intermediates that associated ΔBMI with NAFLD. ΔBMI in earlier adulthood increased higher insulin and insulin resistance (IR) than later adulthood.

CONCLUSIONS

Body weight gain in adulthood was positively associated with NAFLD and MetS, and the association was stronger in earlier than later adulthood. Insulin and IR were important mediators that contributed to the association.

Polymorphisms in the leptin (rs7799039) gene are associated with an increased risk of excessive gestational weight gain but not with leptin concentration during pregnancy

Single nucleotide polymorphisms (SNPs) in leptin (LEP) and leptin receptor (LEPR) have been shown to be linked to obesity-related metabolic markers and phenotype. Therefore, we hypothesized that the LEP-rs7799039 and LEPR-rs1137101 SNPs are related to the risk of pre-pregnancy overweight/obesity (body mass index ≥25 kg/m²) as well as to excessive gestational weight gain (GWG) and high concentrations of leptin throughout pregnancy. We investigated a prospective cohort of 147 Brazilian pregnant women through weeks 5-13, 20-26, and 30-36 of gestation. Genetic variants of LEP and LEPR were analyzed by real-time polymerase chain reaction and leptin by enzyme-linked immunosorbent assay. Statistical analyses included multiple linear regression, linear mixed effects, and Poisson regression models. Genotype AA carriers for the LEP-rs7799039 gene maintained a lower body weight throughout pregnancy compared with those with genotypes GG or GA + GG (β_AAvsGG = -7.91 kg; 95% confidence interval [CI], -14.21 to -1.61; P = .01; and β_{AAvsGA + GG} = -7.66 kg; 95% CI, -14.07 to -1.25; P = .02). The A allele was significantly associated with an increased risk for excessive GWG (relative risk_LEP-GAvsGG, 2.16; 95% CI, 1.23-3.80; and relative risk_LEP-AAvsGG, 2.37; 95% CI, 1.04-5.39). Neither the LEP-rs7799039 nor LEPR-rs1137101 SNP was significantly associated with pre-pregnancy overweight/obesity risk and leptin concentrations during pregnancy. In conclusion, our results indicate that women who had the AA genotype for LEP-rs7799039 displayed a lower body weight throughout pregnancy compared with GG or GA + GG carriers. LEP-rs7799039 was significantly associated with an increased risk for excessive GWG, but the results do not support significant associations of the LEP-rs7799039 and LEPR-rs1137101 polymorphisms with pre-pregnancy overweight/obesity risk and leptin concentrations throughout pregnancy.

Continuous subcutaneous insulin infusion does not correspond with pregnancy outcomes despite better glycemic control as compared to multiple daily injections in type 1 diabetes - Significance of pregnancy planning and prepregnancy HbA1c

OBJECTIVE

The aim of the study was to compare pregnancy outcomes with glycemic control, total increase in insulin requirement, and body weight gain in the women with Type 1 Diabetes Mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

MATERIAL AND METHODS

This was a single center retrospective observational study involving 209 pregnant Caucasian women. Among the study participants, 95 subjects were treated with MDI and 114 patients were using CSII therapy. The primary outcomes were pregnancy results, while secondary ones were HbA1c, increase in daily dose of insulin (DDI), and body weight gain.

RESULTS

At baseline, the CSII users were older (P = 0.0373), they were diagnosed with T1DM at a younger age (P = 0.047), and more often planned pregnancy (P = 0.032). A majority of the women were classified as class D, according to the White classification. Among the CSII users, a significantly higher proportion of the subjects in class B was noted than in the MDI users, with no differences in the proportion of the remaining White classes. Prepregnancy HbA1c was insignificantly lower in the CSII group, however, a significantly higher proportion of the CSII users reached the target value of HbA1c (P = 0.008). A prepregnancy daily dose of insulin (both total and per kg of body weight), body weight, and body mass index (BMI) did not differ between the groups. The 1st and 2nd trimester HbA1c was lower among the CSII users (6.83 ± 1.38 vs 7.52 ± 2.11%, P = 0.01 and 6.17 ± 0.9 vs 6.57 ± 1.12%, P = 0.009, respectively), while the 3rd trimester HbA1c as well as the total change in HbA1c were comparable. Neither DDI and body weight in concecutive trimesters, nor their total gestational increase, differed between the groups. The rate of pregnancy loss, such as abortions, fetal and neonatal death did not differ between the groups. As regards composite pregnancy loss, prepregnancy HbA1c was 8.41%±2.81% among the MDI cohort vs 7.22%±1.31% in the CSII users (P = 0.517). No differences were found in the gestational age at delivery, the mode of delivery, neonatal birth weight, the rate of macrosomy, LGA or SGA. A higher Apgar score was noted among the CSII users (8.63 ± 1.63 vs 8.03 ± 2.49%, P = 0.047), however, the proportion of neonates with an Apgar score lower than 7 points was similar. In the women planning pregnancy, as compared to the subjects who did not, HbA1c was significantly lower in the 1st trimester, together with a significantly higher rate of the women achieving the target HbA1c value during planning as well as in the 1st trimester. In the group of women planning pregnancy, significantly lower 1st trimester HbA1c and composite outcome of pregnancy loss were observed in the CSII users vs the MDI treated women. Lack of pregnancy planning and a high HbA1c level in the 1st trimester were independent predictors of both LGA (OR = 4.99 [95%CI 1.12-21.0], P = 0.033 and OR = 3.02 [95%CI 1.19-7.65], P = 0.019, respectively) and macrosomia (OR = 8.43 [95%CI 1.36-51.93], P = 0.021 and OR = 5.47 [95%CI 1.77-16.87], P = 0.003, respectively).

CONCLUSIONS

The course of pregnancy and obstetric outcomes were not dependent on the mode of insulin delivery, but only on pregnancy planning and HbA1c in early pregnancy. Further studies are needed to explore more precise parameters describing both glycemic control in pregnant women as well as perinatal infant well-being.

Effects of feeding a diet containing Gymnema sylvestre extract: Attenuating progression of obesity in C57BL/6J mice

OBJECTIVE

To investigate the effect of Gymnema sylvestre extract (GS) on initial anti-obesity, liver injury, and glucose homeostasis induced by a high-fat diet (HFD).

METHODS

The dry powder of GS was extracted with methanol, and gymnemic acid was identified by high performance liquid chromatography as deacyl gymnemic acid. Male C57BL/6J mice that fed on either a normal diet, normal diet containing 1 g/kg GS (CON+GS), HFD, or HFD containing 1.0 g/kg GS (HFD + GS) for 4 weeks were used to test the initial anti-obesity effect of GS. Body weight gain and food intake, and serum levels about lipid and liver injury markers were measured. Histopathology of adipose tissue and liver stained with hematoxylin and eosin (H&E) and oil-red O were analyzed. After 4 weeks of GS extract feeding, intraperitoneal glucose tolerance test (IPGTT) was performed.

RESULTS

The methanol extracts of GS exerted significant anti-obesity effects in HFD + GS group. They decreased body weight gain, a lower food and energy efficiency ratio, and showed lower serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL)-cholesterol, very-low density lipoprotein (VLDL)-cholesterol and leptin compared with the HFD group. The decreases of abdominal as well as epididymal fat weight and adipocyte hypertrophy, lipid droplets in liver, and serum levels of aspartate aminotransferase (AST) and alanine transaminase (ALT) were also observed. The CON + GS group showed an effect of glucose homeostasis compared to the CON group.

CONCLUSIONS

This study shows that GS provide the possibility as a key role in an initial anti-obesity effects feeding with a HFD.

Effect of dietary coenzyme Q10 supplementation on the growth rate, carcass characters and cost effectiveness of broiler fed with three energy levels

The objective of this experiment was to study the effect of dietary supplementation of Coenzyme Q10 on broiler growth rate, carcass characteristics and cost of production. A biological trial was carried out with 270 broiler chicks fed with coenzyme Q10 at 0, 20 and 40 mg/kg of diet at each of the three energy levels. At the end of 42 days growth period the birds were sacrificed and the samples were analysed. Feed intake was comparable in all the energy and CoQ10 combinations, but higher body weight gain and better feed efficiency with less feed cost per kilogram weight gain was observed in high energy group supplemented with 20 mg of CoQ10/kg diet. The dressing percentages, weight of giblet, liver, spleen, abdominal fat, intestinal length were not significantly altered by CoQ10 supplementation. The heart weight, gizzard weight and ascites heart weight (AHI) were significantly decreased due to CoQ10 supplementation. Hence, birds fed with high energy diet supplemented with 20 mg CoQ10 per kg of diet had higher production performance.

Effect of Lactobacillus Species Probiotics on Growth Performance of Dual-Purpose Chicken

Introduction

In-feed probiotics are becoming attractive alternatives to antibiotics in the poultry industry due to the ever-growing strict prohibitions on antibiotic growth promoters (AGP) in animal production.

Methods

The study was conducted to investigate the effects of Lactobacillus paracaseis sparacasei and Lactobacillus rhamnosus on the growth performance of 120 day-olds randomly selected Sasso dual-purpose chicken. They were divided into four groups with two replicates per group and 15 chicks per replicate. The treatments were T₁ (control), T₂ (supplement diet with 4g probiotic), T₃ (supplement diet with 2g probiotic), T₄ (supplement diet with 1g probiotic). The experimental feeding trials were conducted after two weeks adaptation period.

Results

The present findings revealed that the chickens supplemented with Lactobacillus species probiotics during the first week of age have shown higher body weight than control (p < 0.05). The feed intake of week one of T₂ and T₃ were significantly higher (p< 0.05) than the T₁ (control). However, there was no significant difference (p> 0.05) in feed intake in the 2^nd, 3^rd, 4^th, and 5^{t h} weeks of all treatment groups. The present result showed that there was a significant body weight gain (p< 0.05) in all probiotic fed groups than the control group. The highest body weight gain was observed in chickens found in the T4 treatment group. Whereas the body weight gains significantly higher and improved the feed conversion (p<0.05) in the T₂ and T₄ than the T₁ (control). However, the feed conversion ratio was significantly influenced by probiotic inclusion in T₃ as compared to the control group.

Conclusion

Overall, the results suggest that Lactobacillus paracaseis sparacasei and Lactobacillus rhamnosus have a positive effect on the growth performance of broilers.

Wheat litter and feed with aluminosilicates for improved growth and meat quality in broiler chickens

BACKGROUND

Natural minerals have many beneficial properties in poultry production, taking into account production as well as hygiene, health, safety, and quality of broiler meat. The aim of the study was to evaluate the effect of aluminosilicates in feed and litter on the growth performance and meat quality in chickens. Aluminosilicates, including halloysite and zeolite, could be a good alternative for synthetics, as a good solution for the environment in line with the current trends.

METHODS

Five-hundred male Ross 308 chickens were managed in 5 groups (10 replicates/group): LITTER: 1, control; 2, 0.95 kg/m2 of halloysite; 3, 0.475 kg/m2 of halloysite and 0.475 zeolite; 4, 0.95 kg/m2 of zeolite; 5, 0.25 kg/m2of halloysite and 0.7 kg/m2 of zeolite. FEED: groups 2-5, halloysite and zeolite addition (25:75 ratio; 0.5-2%). Growth performance (body weight and feed indicators), carcass, and meat quality (pH, colour, water-holding capacity, chemical composition of muscles) were recorded. The experimental setup, where the aluminosilicate additives were applied simultaneously, was proposed and approved by experts after pilot testing and on the basis of extensive literature where feed or litter additives were tested.

RESULTS

Body weight and its gain were higher in groups 3 and 4 than in 1, and feed intake was higher in 4. The weight of the carcass and some of its components, including muscles and skin with subcutaneous fat, were higher in 2-4. Water loss from leg muscles was lower in 4. The content of protein in muscles was significantly higher in 3. The addition of aluminosilicates in feed and litter had a positive effect on the growth performance and some traits of carcasses and meat quality, especially in group 3. Halloysite and zeolite can be used in feed and litter (especially 0.475 kg/m2 for each mineral in the wheat litter).

Weight gain in HIV-infected individuals using distinct antiretroviral drugs

Following the initiation of antiretroviral therapy, most HIV-infected individuals experience significant weight gain. It was originally thought to result from reduced energy consumption associated with suppression of overt virus replication. However, recent evidence suggests that is not simply a back to normal phenomenon. Indeed, a differential influence on weight has been noticed for distinct antiretroviral drugs, some of which may produce abnormal body weight gain and metabolic disturbances. Treatment with integrase inhibitors in particular leads to significant increases in body mass index. By contrast, protease inhibitors might protect from undesirable weight gain. Ultimately, the development of overweight and obesity in an aging HIV population may increase the risk of cardiovascular events and should be prevented. In this scenario, the differential influence on weight gain using distinct antiretroviral agents might provide an opportunity for personalized medicine, adapting the most convenient drug regimen to each patient.

Beneficial effects of a combination of Clostridium cochlearium and Lactobacillus acidophilus on body weight gain, insulin sensitivity, and gut microbiota in high-fat diet-induced obese mice

OBJECTIVES

Species Lactobacillus acidophilus and butyrate producer Clostridium cochlearium have been shown to have potential antiobesity effects. The aim of this study was to show that the combination of C. cochlearium and L. acidophilus (CC-LA) has beneficial effects on body weight control and glucose homeostasis in high-fat diet-induced obese (DIO) mice.

METHODS

In this study, thirty-six 6-wk-old male C57BL/6 mice were randomly assigned to three groups of 12 mice each. The experimental group (CC-LA) was administered with CC-LA mixture and fed ad libitum with a high-fat diet. High-fat diet (HF) control and low-fat diet (LF) control groups were treated with the same dose of sterile water as the CC-LA group.

RESULTS

After 17 wk of dietary intervention, the CC-LA group showed 17% less body weight gain than the HF group did (P < 0.01). The CC-LA group also showed significantly reduced incremental area under the curve of oral glucose tolerance test and homeostatic model assessment for insulin resistance compared with the HF group. The results from 16S rRNA sequencing analysis of gut microbiota showed that the CC-LA administration led to overall increased α-diversity indices, and a significant microbial separation from the HF group. The ratio of Firmicutes to Bacteroidetes (F/B) was reduced from 3.30 in the HF group to 1.94 in the CC-LA group. The relative abundances of certain obesity-related taxa were also decreased by CC-LA administration.

CONCLUSION

The present study provided evidence that the CC-LA combination reduced obesity and improved glucose metabolism in high-fat diet-treated DIO mice, potentially mediated by the modulation of gut microbiota.

A restricted cafeteria diet ameliorates biometric and metabolic profile in a rat diet-induced obesity model

The administration of anti-obesity bioactive compounds and/or functional foods in rodents fed energy restriction diets based on chow food can be difficult to interpret. We propose an energy restricted cafeteria (CAF) diet as a dietetic intervention to be combined with other therapies. Postweaning male rats were fed standard chow, CAF diet or 30% energy restricted CAF diet (CAF-R) for 8 weeks. The CAF-R diet lowered energy intake and the increase of body weight and body mass index due to the CAF diet, lead to an intermediate feed efficiency, and dampened the CAF diet-induced alterations on body composition, serum levels of triacylglycerides and NEFAs, and insulin resistance. These effects were associated with diminished Ucp1, Nrf1 and Tfam1 gene expression in brown adipose tissue. In conclusion, the CAF-R diet ameliorated obesity and related metabolic disorders induced by a regular CAF diet, turning it in a useful tool to study anti-obesity compounds.

Gut microbiome alterations induced by tributyltin exposure are associated with increased body weight, impaired glucose and insulin homeostasis and endocrine disruption in mice

Tributyltin (TBT), an organotin compound once widely used in agriculture and industry, has been reported to induce obesity and endocrine disruption. Gut microbiota has a strong connection with the host's physiology. Nevertheless, the influences of TBT exposure on gut microbiota and whether TBT-influenced gut microbiota is related to TBT-induced toxicity remain unclear. To fill these gaps, ICR (CD-1) mice were respectively exposed to TBT at NOEL (L-TBT) and tenfold NOEL (H-TBT) daily by gavage for 8 weeks in the current study. The results showed that TBT exposure significantly increased body weight as well as epididymal fat, and led to adipocyte hypertrophy, dyslipidemia and impaired glucose and insulin homeostasis in mice. Additionally, TBT exposure significantly decreased the levels of T4, T3 and testosterone in serum. Also of note, TBT exposure changed gut microbiota composition mainly by decreasing Bacteroidetes and increasing Firmicutes proportions. To confirm the role of gut microbiota in TBT-induced overweight and hormonal disorders, fecal microbiota transplantation was performed and the mice receiving gut microbiota from H-TBT mice had similar phenotypes with their donor mice including significant body weight and epididymal fat gain, glucose and insulin dysbiosis and hormonal disorders. These results suggested that gut microbiome altered by TBT exposure was involved in the TBT-induced increased body weight, impaired glucose and insulin homeostasis and endocrine disruption in mice, providing significant evidence and a novel perspective for better understanding the mechanism by which TBT induces toxicity.

Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin

Background

Prescription of second-generation antipsychotic drugs (SGAs) to childhood/adolescent has exponentially increased in recent years, which was associated with the greater risk of significant weight gain and dyslipidemia. Statin is considered a potential preventive and treatment approach for reducing SGA-induced weight gain and dyslipidemia in schizophrenia patients. However, the effect of statin treatment in children and adolescents with SGA-induced dyslipidemia is not clearly demonstrated.

Methods

To investigate the efficacy of statin interventions for reversing SGA-induced dyslipidemia, young Sprague Dawley rats were treated orally with either olanzapine (1.0 mg/kg, t.i.d.), simvastatin (3.0 mg/kg, t.i.d.), olanzapine plus simvastatin (O + S), or vehicle (control) for 5 weeks.

Results

Olanzapine treatment increased weight gain, food intake and feeding efficiency compared to the control, while O + S co-treatment significantly reversed body weight gain but without significant effects on food intake. Moreover, olanzapine treatment induced a slight but significant reduction in body temperature, with a decrease in locomotor activity. Fasting plasma glucose, triglycerides (TG), and total cholesterol (TC) levels were markedly elevated in the olanzapine-only group, whereas O + S co-treatment significantly ameliorated these changes. Pronounced activation of lipogenic gene expression in the liver and down-regulated expression of uncoupling protein-1 (UCP1) and peroxisome-proliferator-activated receptor-γ co-activator-1α (PGC-1α) in brown adipose tissue (BAT) was observed in the olanzapine-only group. Interestingly, these protein changes could be reversed by co-treatment with O + B.

Conclusions

Simvastatin is effective in ameliorating TC and TG elevated by olanzapine. Modulation of BAT activity by statins could be a partial mechanism in reducing metabolic side effects caused by SGAs in child and adolescent patients.

Graphical abstract

Olanzapine-induced changes in glucose metabolism are independent of the melanin-concentrating hormone system

Atypical antipsychotic drugs such as Olanzapine (Ola) induce weight gain and metabolic changes associated with the development of type 2 diabetes. The mechanisms underlying these undesired side-effects are currently unknown. Chagnon et al. showed that the common allele rs7973796 of the prepro-melanin-concentrating hormone (PMCH) gene is associated with a greater body mass index in Ola-treated schizophrenic patients. As PMCH encodes for the orexigenic neuropeptide melanin-concentrating hormone (MCH), it was hypothesized that MCH is involved in Ola-induced metabolic changes. We have recently reported that the intragastric infusion of Ola results in hyperglycaemia and insulin resistance in male rats. In order to test in vivo the possible involvement of the PMCH gene in the pathogenesis of Ola side-effects, we administered Ola intragastrically in wild-type (WT) and PMCH knock-out (KO) rats. Our results show that glucose and corticosterone levels, as well as endogenous glucose production, are elevated by the infusion of Ola in both WT and KO animals. Thus, the lack of MCH does not seem to affect the acute effects of Ola on glucose metabolism. On the other hand, these effects might be obliterated by compensatory changes in other hypothalamic systems. In addition, possible modulatory effects of the MCH KO on the long term effects of Ola, i.e. increased adiposity, body weight gain, have not been investigated yet.

Sigma-1 receptor ablation impedes adipocyte-like differentiation of mouse embryonic fibroblasts

The sigma-1 receptor (Sig1R) is a unique ligand-operated endoplasmic reticulum (ER) protein without any mammalian homolog. It has long been a pharmacological target for intervention of psychiatric disorders, and recently garnered refreshed interest for its neuroprotective potential. Though reported to modulate various intracellular events, its influence on cell identity is little known. We explored a role for Sig1R in adipocyte differentiation. We induced adipogenic differentiation of mouse embryonic fibroblasts (MEFs) with a differentiation medium. MEFs were isolated from Sigmar1-/- and Sigmar1+/+ mice. The induced adipocyte-like phenotype was detected through Western blots of master transcription factors (PPARγ, CEBPA, SREBP1, SREBP2), lipogenic proteins (FABP4, ACC1, ACAT2), and Oil-Red-O staining of lipids. We found that the induced upregulation of these proteins and lipid accumulation were severely mitigated in Sigmar1-/- (vs Sigmar1+/+) MEFs. Sig1R activation with a selective agonist (PRE084) increased Sig1R protein and further enhanced the induced adipocyte-like phenotype in Sigmar1+/+ MEFs. We also determined mouse body weight gain induced by high-fat diet for 6 months, which was impeded in Sigmar1-/- (vs Sigmar1+/+) male mice. In summary, genetic ablation of Sig1R impairs, and agonist activation of Sig1R enhances adipocyte-like phenotype of induced MEFs. In vivo, Sig1R ablation impedes the body weight gain of male mice on high-fat diet. This study warrants further investigation of a previously unrecognized role for Sig1R in adipocyte differentiation.

Effect of replacing concentrate feed with leaves of Oldman saltbush (Atriplex nummularia) on feed intake, weight gain, and carcass parameters of highland sheep fed on wheat straw in northern Ethiopia

Atriplex nummularia (oldman saltbush) is widely planted on salt-affected land to provide a vegetative cover, which can be used as an alternative feed resource. The study was conducted to evaluate the replacement of commercial concentrate with oldman saltbush (SB) leaf on the feed intake, live weight gain, and carcass parameters of local sheep. Twenty-five sheep with an age of 6 months and weighting 14.60 ± 2.47 kg were used in randomized complete block design and distributed into five equal groups, with five animals each. The selected sheep were fed with the dietary treatments for 2 weeks for adaptation and continued until the end of the study, which lasted for 90 days. In the control treatment (SB-0), sheep were fed 100% concentrate mix, while in SB-5, SB-10, SB-15, and SB-20, 5, 10, 15, and 20% of the concentrate mix was replaced by SB, respectively. Wheat straw and water were given at ad libitum throughout the experiment period. Data on feed intake and live weight gain were recorded daily and weekly, respectively, for 90 days. Three animals from each treatment were slaughtered for carcass analysis. Atriplex nummularia leaf (Oldman saltbush) contained 92.02% dry matter (DM), 21.99% crude protein (CP), 24.77% ash, 58.27% neutral detergent fiber (NDF), and 26.56% acid detergent fiber (ADF). Dry matter intake, live weight gain, and carcass parameter were not statistically different among the treatments. Result indicated that concentrate feed can be replaced with Atriplex nummularia leaf up to 20% in sheep diet without negative effect on growth performance and carcass characteristics.

Associations between family factors and body weight gain from 20 years old

BACKGROUND

Although family factors can greatly impact adult health, little is known about the extent to which family factors are related to body weight gain (BWG) in adulthood. This study aimed to examine the associations between family factors and BWG from 20 years old.

METHODS

Among the 6395 possible participants aged 35 to 79 years, 2884 men and 2171 women were eligible for the study. Present body mass indexes (BMI) were measured, and family factors and body weight from 20 years old (i.e., BMI_20yr) were collected using a self-administered questionnaire. The differences between BMI and BMI_20yr were calculated, and those with increases of BMI ≥2.5 kg/m² (i.e., ≥7.5 and 6.0 kg in men and women, respectively) were defined as 'cases' of BWG. Using a multiple logistic regression analysis, the odds ratios (ORs, 95% confidence intervals [CIs] and p for trend) were estimated.

RESULTS

In the men, no association was found. In the women, the ORs were 0.31, 1.00 and 0.77 (0.17-0.58, [reference], and (0.52-1.29), p < 0.001) as per their marital status: unmarried, married, and bereaved/divorced, respectively. Although no association was found with family structure (i.e., single, couple, and two and three generations living together), for familial relationships, the ORs were 1.00, 1.11 and 1.86 ([reference], 0.85-1.46, and 1.25-2.79, p < 0.01) for 'good', 'somewhat good', and 'not so good/not good', respectively. Even if a 'case' of BWG was ≥3.5 kg/m², nearly the same risks remained.

CONCLUSION

Marital status and family relationships were associated with decreased and increased risks of BWG only in the female participants. Family factors should be considered when advising women on body weight control.

Downregulation of Bdnf Expression in Adult Mice Causes Body Weight Gain

Gain or loss of appetite and resulting body weight changes are commonly observed in major depressive disorders (MDDs). Brain-derived neurotrophic factor (BDNF) is broadly expressed in the brain and is thought to play a role in the pathophysiology of MDDs and obesity. Congenital loss of function of BDNF causes weight gain in both humans and rodents; however, it is not clear whether acquired loss of function of BDNF also affects body weight. Thus, we exploited mutant mice in which the Bdnf expression level is regulated by the tetracycline-dependent transcriptional silencer (tTS)-tetracycline operator sequence (tetO) system. Time-controlled Bdnf expression using this system allowed us to establish congenital and acquired loss of function of Bdnf in mice. We demonstrated that changes in Bdnf expression influenced body weight during not only the developmental stage but also the adult stage of mice. Although it is still unclear whether acquired Bdnf loss of function in rodents mimics the pathology of MDD, our findings may bridge the mechanistic gap between MDDs and body weight gain in line with BDNF dysfunction.

Effect of lablab and pigeon pea leaf meal supplementation on performance of goats fed a basal diet of haricot bean haulms

An experiment was conducted to evaluate the effect of lablab and pigeon pea leaf supplementation on feed intake, digestibility, weight gain, and carcass characteristics of goats fed a basal diet of haricot bean haulms. Thirty-two yearling intact male goats with an average initial body weight of 14.4 ± 1.04 kg (Means ± SD) were assigned to one of the four treatments in a randomized complete block design. The dietary treatments were 17.5% lablab + 17.5% pigeon pea leaf + 63% wheat bran (T1), 35% pigeon leaf + 63% wheat bran (T2), 35% lablab leaf + 63% wheat bran (T3), and 88% wheat bran + 10% noug seed cake (T4). In addition, all treatment diets contained 1 and 1% limestone. The feeding trial lasted for 90 days followed by 7 days of digestibility trial. Carcass evaluation was conducted at the end of the feeding trial. Final body weight ranged from 16.3 kg for T4 to 21.1 kg for T3. The total dry matter (DM) intake for T3 was higher (P < 0.05) than T2 and T4. The total crude protein (CP) intake for T2 was greater (P < 0.05) than T3 and T4. Goats supplemented with T3 diets had the highest (P > 0.05) digestibility of DM, organic matter, and CP and attained the highest (P < 0.05) average daily gain, the heaviest (P < 0.05) hot carcass weight, and the highest (P < 0.05) rib-eye muscle area than those supplemented with T1, T2, and T4 diets. In conclusion, 35% lablab leaf meal and 63% what bran (T3) were found to be a very promising supplement in sheep fed low-quality crop residues under the condition of the current experiment.

Dietary metabolizable energy, digestible lysine, available phosphorus levels and exogenous enzymes affect broiler chicken performance

The nutritional composition of diets and the provision of exogenous enzymes play important roles in animal performance. Here, we evaluated the individual and combined impact of nutrients (metabolizable energy (ME), digestible lysine (dLys), available phosphorus and calcium (avP-Ca)) and exogenous multicarbohydrase and phytase complex (MCPC) enyzmes on the growth performance and feed efficiency of broiler chickens from 10 to 42 days (d) of age. Experimental diets were formulated in a Box-Behnken design to contain various levels of ME (11.89, 12.21, 12.54 or 13.06 MJ/kg), dLys (0.91%, 0.93%, 0.96% or 1.00%) and avP/Ca (0.12/0.47%, 0.21/0.58% or 0.33/0.68%). The effect of MCPC was expressed in terms of the extra nutrients released. The diets were formulated to have consistent substrate contents (i.e., arabinoxylan and phytate). Feed intake (FI), BW gain (BWG) and feed conversion ratio (FCR) were described via polynomial equations (R² = 0.99, 0.98 and 0.81, respectively), with interconnections between variables (ME, dLys and avP-Ca). Available P-Ca was the most important factor affecting FI (quadratically), and BWG and FCR (linearly). Reducing the avP content from 0.33% to 0.12% in diets lacking MCPC resulted in 25% and 33% decreases in FI and BWG, respectively, and a 12% increase in FCR. The ME and dLys contents also linearly affected these performance parameters to a lesser degree; FI decreased by 400 g when the ME was reduced by 1.17 MJ/kg, and by 300 g following a 0.09% reduction of dLys, while the same reductions in ME and dLys decreased BWG by 120 g and 150 g, respectively. The inclusion of MCPC alleviated the reduction of FI, BWG and FCR by decreasing the avP-Ca. Thus, ME and dLys were the most important factors affecting BWG and FCR in broilers fed diets containing MCPC. When MCPC was added, ME negatively affected FI (r = -0.89, P < 0.001), whereas the dLys content was correlated with BWG (r = 0.74, P < 0.001). Both ME and dLys affected FCR (r = -0.83 and -0.85, respectively). Supplementing MCPC allowed the reduction of ME, dLys and avP-Ca in the diet without affecting performance. Indeed, MCPC's effect promoted with the release of the following nutrients: 0.56 MJ ME/kg, 0.06% dLys, and 0.15% and 0.13% avP and Ca, respectively. The results indicate nutrient effect and interaction on performance and feed additive potential for nutrient release.

Oral Administration of Artemisia argyi Polysaccharide Increases Estrogen Level and Maintains Blood Lipid Homeostasis in Ovariectomized Rats

INTRODUCTION

Artemisia argyi polysaccharide (AAP) has a beneficial effect on menstruation-related symptoms and the potential regulation of lipid metabolism. It is expected to be a safe and effective ingredient for estrogen deficiency and lipid metabolic disorders. Here, we investigate the effect of AAP on body weight gain, estrogen level, and blood lipid changes in ovariectomized (OVX) rats.

METHODS

Thirty-six female Wistar rats were randomly divided into six treatment groups, including a sham-operated (Sham) group, OVX group, estrogen replacement (OVX + E2) group, and AAP treatment (OVX + 125, 250, 500 mg/kg AAP) group. The body weight and feed intake were recorded every week. The level of estrogen and blood lipid was determined. The gene expressions and protein expressions of estrogen receptors (ERs), fatty acid synthetase (FAS), acetyl CoA carboxylase 2 (ACC2), and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGR) were determined.

RESULTS

AAP treatment significantly decreased the body weight gain and average daily food intake of rats in the OVX group. Treatment with AAP significantly increased the relative weight of the uterus, plasma estrogen level, and the gene expression and protein expression of ER-α in the uterus. For blood lipids, plasma levels of triglyceride, total cholesterol, and low-density lipoprotein cholesterol were significantly reduced by AAP treatment in OVX rats. AAP treatment decreased the expression of FAS and HMGR in the liver of OVX rats. Furthermore, AAP treatment significantly increased the gene expression of ACC2, the protein expression of P-ACC2, and the ratio of P-ACC2/ACC2.

CONCLUSION

In summary, AAP treatment exerts beneficial effects on body weight gain and lipid metabolism disorder induced by ovariectomy through increasing estrogen levels, inhibiting FAS, and promoting fatty acid oxidation.